Celltrion Pharm launched "Omriclo Pen Injection 150mg" (ingredient name omalizumab), a treatment for allergic diseases, in Korea, the company said Monday.
Omriclo is used to treat allergic asthma and chronic idiopathic urticaria. The AI (auto-injector) formulation is a formulation that differentiates it from the original product sold in Korea, allowing patients to self-administer. The price of Omriclo Pen Injection 150mg was set at 173,404 won, the same as the existing Omriclo 150mg PFS.
"With the launch of Omriclo Pen Injection 150mg, we can now supply the AI formulation in Korea in addition to the existing prefilled syringe (PFS) formulation," a Celltrion Pharm official said.
